Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label,

Similar presentations


Presentation on theme: "Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label,"— Presentation transcript:

1 Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study  Fumihiko Koiwa, MD, PhD, Keitaro Yokoyama, MD, PhD, Masafumi Fukagawa, MD, PhD, Tadao Akizawa, MD, PhD  Journal of Renal Nutrition  Volume 27, Issue 5, Pages (September 2017) DOI: /j.jrn Copyright © 2017 The Authors Terms and Conditions

2 Figure 1 Median changes over time in serum ferritin and box-and-whisker plot showing the 5-number summary of serum ferritin values by maximum dose of PA21 (A), and mean changes in transferrin saturation by maximum dose of PA21 (B). EOT, end of treatment; PA21, sucroferric oxyhydroxide. Journal of Renal Nutrition  , DOI: ( /j.jrn ) Copyright © 2017 The Authors Terms and Conditions

3 Figure 2 Serum phosphorus concentrations and PA21 (sucroferric oxyhydroxide) daily dose. P, phosphorus; EOT, end of treatment; SD, standard deviation. Journal of Renal Nutrition  , DOI: ( /j.jrn ) Copyright © 2017 The Authors Terms and Conditions

4 Figure 3 Serum phosphorus concentrations and phosphate binder daily doses in patients who switched treatment from (A) calcium carbonate (n = 67), (B) lanthanum (n = 24), and (C) combination of calcium carbonate and lanthanum (n = 42) to PA21 (sucroferric oxyhydroxide). CaC, calcium carbonate; P, phosphorus; EOT, end of treatment; SD, standard deviation. Journal of Renal Nutrition  , DOI: ( /j.jrn ) Copyright © 2017 The Authors Terms and Conditions

5 Supplementary Figure 1 Disposition of study participants and flow through the study. Journal of Renal Nutrition  , DOI: ( /j.jrn ) Copyright © 2017 The Authors Terms and Conditions

6 Supplementary Figure 2 Distribution of the number of tablets for daily doses (3 or 6 tablets; percentage) among study participants throughout the study period. EOT, end of treatment. Journal of Renal Nutrition  , DOI: ( /j.jrn ) Copyright © 2017 The Authors Terms and Conditions

7 Supplementary Figure 3 Rates of achievement (percentage) of the target serum phosphorus concentration throughout the study period. EOT, end of treatment. Journal of Renal Nutrition  , DOI: ( /j.jrn ) Copyright © 2017 The Authors Terms and Conditions


Download ppt "Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label,"

Similar presentations


Ads by Google